In the BioHarmony Drug Report Database
Esketamine
Spravato (esketamine) is a small molecule pharmaceutical. Esketamine was first approved as Spravato on 2019-03-05. It is used to treat treatment-resistant depressive disorder in the USA. It has been approved in Europe to treat depressive disorder. Spravato’s patents are valid until 2035-09-10 (FDA).
Trade Name
|
Spravato |
|---|---|
Common Name
|
esketamine |
ChEMBL ID
|
CHEMBL395091 |
Indication
|
depressive disorder, treatment-resistant depressive disorder |
Drug Class
|
Nmda receptor antagonists; Antidepressants; General anesthetics; Dissociative hallucinogens; Analgesics |
Image (chem structure or protein)